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Abstract
The Ras superfamily of guanosine-triphosphate (GTP)-binding proteins regulates a diverse spectrum of intracellular
processes involved in inflammation and fibrosis. Farnesythiosalicylic acid (FTS) is a unique and potent Ras inhibitor which
decreased inflammation and fibrosis in experimentally induced liver cirrhosis and ameliorated inflammatory processes in
systemic lupus erythematosus, neuritis and nephritis animal models. FTS effect on Ras expression and activity, muscle
strength and fibrosis was evaluated in the dy
2J/dy
2J mouse model of merosin deficient congenital muscular dystrophy. The
dy
2J/dy
2J mice had significantly increased RAS expression and activity compared with the wild type mice. FTS treatment
significantly decreased RAS expression and activity. In addition, phosphorylation of ERK, a Ras downstream protein, was
significantly decreased following FTS treatment in the dy
2J/dy
2J mice. Clinically, FTS treated mice showed significant
improvement in hind limb muscle strength measured by electronic grip strength meter. Significant reduction of fibrosis was
demonstrated in the treated group by quantitative Sirius Red staining and lower muscle collagen content. FTS effect was
associated with significantly inhibition of both MMP-2 and MMP-9 activities. We conclude that active RAS inhibition by FTS
was associated with attenuated fibrosis and improved muscle strength in the dy
2J/dy
2J mouse model of congenital muscular
dystrophy.
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Introduction
Merosin deficient congenital muscular dystrophy (MDC1A,
OMIM # 607855) is the most common form of the congenital
muscular dystrophies. It is an autosomal recessive disorder caused
by mutations in the LAMA2 gene, localized to chromosome 6q22–
q23. Most children affected with this disorder have severe clinical
symptoms. They do not achieve independent ambulation and die
in childhood or early adulthood [1,2]. The Lama2
dy-2J (dy
2J/dy
2J)
is a useful mouse model for MDC1A. It has a spontaneous G to A
mutation in the donor splice site of exon 2 which results in exon
skipping [3,4,5]. The clinical course of the homozygous dy
2J/dy
2J
mouse involves early onset progressive muscle weakness and motor
deterioration; though less severe than its allelic form the dy/dy
mouse. Muscle biopsy shows progressive dystrophic changes
including muscle fiber necrosis, regeneration, and progressive
fibrosis [4,6]. Comparable to merosin deficient congenital
muscular dystrophy children, dy
2J/dy
2J mice demonstrate a
peripheral neuropathy in addition to the muscular dystrophy
[7,8,9].
The Ras superfamily of guanosine-triphosphate (GTP) binding
proteins that includes more than 50 members regulates a diverse
spectrum of intracellular processes [10]. Ras proteins are
expressed in almost all adult and fetal tissues, acting as molecular
switches, and activating signal transduction pathways that regulate
cellular proliferation, differentiation and survival [11]. They are
attached to the inner side of the plasma membrane where they are
activated by cell surface receptors to induce the conversion of the
inactive Ras, guanosine-diphosphate (GDP), to active Ras-GTP
[12]. Over expression of Ras proteins causes proliferation and
tumor genesis. In addition, previous studies demonstrated
increased Ras expression in inflammatory processes, such as
systemic lupus erythematosus (SLE), neuritis and nephritis
[13,14,15]. Ras has also been shown to be involved in the
modulation of the immune response. It affects the expression of
major histocompatibility complex (MHC) molecules, antigen
processing, cytokine production, and regulation of receptors, T
cells, and growth factors [16].
Farnesythiosalicylic acid (FTS) is a synthetic derivative of
carboxylic acid, which structurally resembles the carboxy-terminal
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functional Ras antagonist, affecting Ras membrane interactions by
dislodging the protein from its anchorage domains, facilitating its
degradation, and thus reducing the cellular Ras content and the
cells’ response to it [17,18]. FTS is a potent growth inhibitor of
cells expressing active H-Ras, K-Ras, or N-Ras in vitro and of
human pancreatic and colon carcinoma as well as hematologic
malignancies and melanoma tumors [19,20]. We have previously
shown that FTS is a reversible drug [19,20,21] with reversibility of
its inhibitory effects on Ras-dependent growth in vitro [18,19,20]
and in vivo [21] and on Ras -dependent behavior in vivo [15].
Moreover, FTS has been found to be beneficial in decreasing
inflammation and fibrosis in experimentally induced liver cirrhosis
and in treating and preventing inflammatory processes such as
SLE, neuritis or nephritis in animal models [13,14,15,22,23].
In the current study, given previous documentation of anti-
inflammatory and anti-fibrotic characteristics of FTS, the role of
Ras and the therapeutic potential of FTS was evaluated in this
mouse model of merosin deficient congenital muscular dystrophy.
FTS treatment significantly decreased muscle Ras expression and
activity and was associated with significant reduction of fibrosis and
improvement in hind limb muscle strength in the dy
2J/dy
2J mice.
Materials and Methods
Mice
C57BL/6J Lama2
dy-2J (dy
2J/dy
2J) heterozygote mice were
obtained from Jackson Laboratories (Bar Harbor, Maine, USA)
and were bred at the Hebrew University SPF animal housing
facility. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Hebrew University (Permit Number: 122.03–
04). All surgery was performed under ketamine-xylazine anesthe-
sia, and all efforts were made to minimize suffering. Mice were
maintained under standard conditions, 2361uC, 12 h light cycle
(7 a.m.–7 p.m.) with ad libitum access to food and drink. No
animal had paralysis with inability to reach food or water or
dramatic weight loss (more than 10% weight loss between two
weighings, or more than 20% from initial weight) or any other
severe stress signs requiring withdrawal from the study. No other
side effects were noted in the treatment group. Delineation
between the dy
2J/dy
2J affected mice, heterozygous for the lama2
gene mutation and wild type C57BL/6J (WT) mice was detected
by PCR reaction with the following primers: forward 59-
TCCTGCTGTCCTGAATCTTG and reverse 59- CTCTAT-
TACTGAACTTTGGATG. The digestion of the PCR products
with the NdeI restriction enzyme (recognition sequence: CAT-
ATG) resulted in characteristic product size for each of the mice
genotypes [4].
Following previous protocols in the rat model of liver cirrhosis
[22],WTanddy
2J/dy
2Jmicewereinjectedintra-peritoneally3times
a week with FTS 5 mg/kg or control solution (see below), for 12
weeks from the age of 6 weeks (n=7/group, each group consisted of
4 males and 3 female mice). At the end of the study both hind limb
muscles were dissected. Part of the muscle sample was frozen in
liquid nitrogen and stored at 280uC for biochemical analysis.
Quadriceps femoris muscle was rapidly frozen in isopentane pre-
chilled by liquid nitrogen for cryostat sections and histology.
Preparation of Farnesylthiosalicylic Acid (FTS)
FTS was a gift from Concordia Pharmaceuticals (http://www.
concordiapharma.com). FTS was prepared as previously described
[24]. For each set of experiments, FTS was prepared as a 0.1 M
stock solution in chloroform, the chloroform was removed from the
stock by a nitrogen stream prior to use, and the dry FTS then
dissolved in ethanol. The FTS/ethanol solution was alkalinized by
the addition of 1N NaOH and then diluted by the addition of
phosphate-buffered saline (PBS). The control solution was prepared
as described above except that FTS and NaOH were excluded.
Muscle strength
Total peak force (in gram force/gram bodyweight) was
determined once a week using an electronic Grip Strength Meter,
Columbus Instruments (Columbus, OH, USA). Each week muscle
strength measurements of both fore and hind limbs were
performed according to Dadush O et al. [25], with five
measurements done on each fore and hind limb from each
animal. The three highest measurements were averaged to give the
strength score. The mice were allowed to rest for 10 minutes
between fore and hind limb measurements. All measurements
were performed by the same examiner.
Mobility
At the end of the study the mice were video recorded for
10 minute sessions which were analyzed by the Ethovision XT
Behavioral activity system (version 5, Noldus Information
Technology, Wageningen, the Netherlands) [25]. The test arena
was transparent, 27 cm wide, 48 cm long and 25 cm high. To
reduce body movements which were not associated with mobility,
only recordings which resulted in movement of at least 0.5 cm in
0.2 sec were included in the calculated data. Total distance and
mean velocity as well as maximal distance and velocity in
0.2 seconds were calculated using the software.
Histology and quantitative analysis of fibrosis
Quadriceps muscle biopsies were flash-frozen in cooled
isopentane and mounted in ‘‘Tissue-Teck’’. Ten mm tissue sections
were stained with Hematoxylin-Eosin (H&E) for histology, and
with Sirius red counterstained with fast green for collagen
quantitative measurement using Ariol SL-50 automated image
analysis (Applied Imaging, CA, USA). The Ariol software was set-
up to distinguish between the red (R), fibrotic (collagen stained)
area, and green (G), non-collagen area. The fibrosis percentage
was calculated by dividing the fibrotic area (R) by the total area
(R+G). The mean of the fibrotic area was calculated from five
regions in each biopsy.
Collagen measurement
Total muscle collagen content was quantitatively measured by
the Sircol
TM Collagen Assay (Biocolor, Newtownabbey, Northern
Ireland). This is a quantitative dye-binding method analyzing acid-
soluble collagens (Type I–IV), extracted from mammalian tissues.
Soluble collagen quantification was performed from 30 mg of hind
limb muscle according to manufacturer’s manual.
Western Blotting and Ras activity
In order to examine the effect of FTS on Ras cascade in muscle,
total Ras expression and ERK phosphorylation were determined in
a3 0mg samples by immunoblotting with pan anti-Ras (Calbio-
chem, La Jolla, CA), pERK (Sigma, St. Louis, MO, USA), ERK
(Santa Cruz, CA, USA)and goat anti-mouse HRP (Bio-Rad,
Richmond, CA, USA) antibodies followed by enhanced chemilu-
minescence (ECL) [26]. Normalization was performed by anti b-
tubulin (Sigma). Since Ras-GTP activates Raf in the signal
transduction pathway, Ras activity was determined by pull-down
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conjugate to GST-gluttion-agarose beads. Briefly, Lysates contain-
ing 800 mg protein were used to determine the Ras-GTP by using
glutathione S-transferase (GST) Ras-binding domain pull-down
assay [26]. Following 30 min rotation at 4uC the sample were
washed 3 times with buffer. The proteins were dissolved in SDS
sample buffer and separated by SDS page which was followed by
immunoblotting with pan anti-Ras antibody and goat anti-mouse
HRP followed by ECL [26]. A negative control for the assay was
incubating the Ras in homogenates of WT mice with 1 mM GDP
for 30 min to induce GDP for GTP exchange. We then subjected
the lysates to the pool down assay. This treatment caused exchange
of most of the GTP to GDP on Ras and a 90% reduction in Ras-
GTP binding was observed (Figure 1B lower panel).
Gelatin Zymography for MMP-2 and MMP-9
MMP-2 and MMP-9 activity was determined from mice
muscles as previously described [27], with minor modifications.
Briefly, samples of 50 mg homogenated muscle were separated on
gelatin-impregnated (1 mg/ml, Difco, Detroit, MI), SDS-8%
polyacrylamide gels under non-reducing conditions, followed by
30 min shaking in 2.5% Triton X-100 (BDH, UK). The gels were
then incubated for 16 h at 37uC in 50 mM Tris, 0.2 M NaCl,
5 mM CaCl2, 0.02% Brij 35(w/v) at pH 7.6. At the end of
incubation the gels were stained with 0.5% Coomassie G 250 (Bio-
Rad) in methanol/acetic acid/H2O (30:10:60). The intensity of
the various bands was determined on a computerized densitometer
(Molecular Dynamics, type 300A).
Statistical analysis
All data are expressed as mean 6 standard error of the mean
(SEM) and all statistical analysis was completed in SPSS (SPSS
15.0 for windows). Statistical analysis for direct comparison
between two groups was performed by unpaired Student’s t-test
and non parametric Mann-Whitney test. Multiple comparisons
between groups were made using repeated-measures ANOVA.
Significance was set at P,0.05 for all comparisons.
Results
Ras expression and Ras-GTP
WT and dy
2J/dy
2J mice were treated with either FTS or
control for 12 weeks. Immunoblotting of skeletal muscle was
carried out at the end of the study using anti-Ras antibody.
Figure 1. The effect of FTS on Ras expression, activity and pERK. Western blot analysis gels and densitometry graphs of Ras expression (A)
Ras activity (B) and p-ERK (C) in the WT and dy
2J/dy
2J mice are presented. Ras expression, activity and pERK measurements were significantly lower in
the FTS treated compared to the untreated dy
2J/dy
2J mice (* A; P,0.01 B; P,0.05 C; P,0.02 Student’s t-test). All 3 measurements were higher in the
dy
2J/dy
2J compared to the WT mice (** A; P,0.01 B; P,0.01 C; P,0.02; Student’s t-test). The lower panel of figure B is the negative control for Ras-GTP
binding assay. Each bar represents the mean 6 SEM of 4 independent experiments from six mice.
doi:10.1371/journal.pone.0018049.g001
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2J/dy
2J mice showed significantly higher Ras
expression compared to the WT group (555.08666.32 vs.
100622.45 densitometry, percent of control; P,0.01;
Figure 1A). FTS treatment was associated with significantly
decreased Ras expression in the dy
2J/dy
2J mice (205.76619.37;
P,0.01). Treatment of WT mice with FTS caused an increase in
Ras expression which was by far much lower than the increase
observed in the dy
2J/dy
2J mice (206.76629.37). In addition to
Ras expression, Ras activity was measured at the end of the study
by the Ras binding domain pull-down assay. In this assay the
GTP-bound Ras is detected by its preferential binding to the
RBD domain of Raf1 which is conjugated to sepharose beads
[26]. We found that Ras-GTP levels were higher in dy
2J/dy
2J
compared to the levels in WT mice (157.40614.53 vs.
100610.23; P,0.05. Figure 1B). The levels of Ras-GTP were
significantly reduced in the FTS treated dy
2J/dy
2J group
(97.16610.54; P,0.01). Moreover, Ras-GTP in the treated
dy
2J/dy
2J normalized and was comparable to the WT group.
Treatment of the WT mice with FTS induced an increase in Ras-
GTP (141.72612.4) comparable to the increase in Ras expression
in these mice. The nature of these increases observed in the WT
mice is not known.
In addition, we measured the phosphorylation of ERK, a Ras
downstream protein (Figure 1C). ERK phosphorylation was very
high in the dy
2J/dy
2J mice compared to the WT group
(424.97663.85 vs. 100621.56; P,0.02) while, FTS treatment
significantly decreased this phosphorylation (175.62621.53;
P,0.02). Small increase in pERK was noted in the WT FTS
(169.29631.1) while, total ERK did not change at all.
Muscle strength
Total peak force was determined once a week using an
electronic Grip Strength Meter. Significant difference in hind
limb muscle strength was detected between the untreated dy
2J/dy
2J
and the WT mice throughout the study (P,0.01; Figure 2).
A significant increase in hind limb muscle strength was noted in
the FTS treated compared to the untreated dy
2J/dy
2J mice
(P,0.05). During the study period muscle strength increased from
3.0160.27 to 4.7960.22 (gram force/gram body weight) in the
treated dy
2J/dy
2J mice, while remained unchanged from
2.6760.22 to 2.7260.19 in the untreated dy
2J/dy
2J group.
Moreover, at the end of the trial the hind limb muscle strength
of the dy
2J/dy
2J treated mice completely normalized to that of both
WT groups (4.7960.22 vs. WT: 4.6460.39; WT+FTS:
4.7760.25). Such a difference was not detected in the fore
(stronger) limbs of the dy
2J/dy
2J mice (Figure S1), and in the fore
and hind limbs of the treated and untreated WT groups.
Muscle histology
In comparison with the normal WT (Fig. 3A), Hematoxylin and
eosin staining of untreated dy
2J/dy
2J mouse quadriceps muscle at
the age of 18 weeks showed severe advanced dystrophic changes
with abnormal variation of fiber size, internal nuclei and severe
excessive fibrosis (Fig. 3B). The FTS treated dy
2J/dy
2J muscle
showed considerable fibrosis attenuation (see next paragraph) but
still abnormal myopathic changes with variation in fiber size, and
increased number of central nuclei (Fig. 3C).
Quantitative muscle fibrosis by Sirius red staining
On Sirius red staining, quantified by the Ariol SL-50 automated
image analysis (Fig. 4A and B), untreated dy
2J/dy
2J mice exhibited
significantly higher total quadriceps collagen content compared to
the WT mice (40.9265.16 vs. 22.7665.89; P,0.05). A significant
decrease in collagen was noted in the FTS treated dy
2J/dy
2J
compared to the untreated dy
2J/dy
2J mice (23.8763.91 vs.
40.9265.16; P,0.02). Collagen accumulation in the FTS treated
dy
2J/dy
2J mice was reduced to the level of both WT groups
(23.8763.91 vs. WT: 22.7665.89; WT+FTS: 23.9363.47). No
effect of FTS treatment on collagen content was observed in the
WT mice.
Figure 2. Hind limb muscle strength in WT and dy
2J/dy
2J FTS treated and untreated groups. The data of seven mice in each group is
expressed as mean 6 SEM. Repeated measures ANOVA test showed significant improved hind limb strength in the treated dy
2J/dy
2J mice (P,0.05).
There was no significant difference between the treated and untreated WT groups.
doi:10.1371/journal.pone.0018049.g002
FTS Treatment in dy
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Assay
Quantitative total muscle collagen content using the Sircol
Collagen Assay was determined at the end of the study.
Significantly higher collagen level was shown in the untreated
dy
2J/dy
2J compared to the WT mice (0.4460.05 vs. 0.2360.05 mg
collagen/mg tissue; P,0.01; Fig. 5). The dy
2J/dy
2J FTS treated
mice showed significantly decreased collagen levels (0.2760.04,
P,0.02) compare to the untreated group and were normalized to
the treated WT group (0.2560.02). Collagen levels were similar in
the treated and untreated WT groups (0.2560.02 vs.0.2360.05).
MMP-2 and MMP-9 activity
The collagenolytic activities of MMP-2 and MMP-9 were
significantly higher in the untreated dy
2J/dy
2Jcompared to the
WT group (22.262.1 vs. 6.164.7 and 18.562.3 vs. 4.264.1
collagenolytic activity, respectively; P,0.01; Figure 6). FTS
treatment was associated with significantly inhibition of both
MMP-2 and MMP-9 activities in the dy
2J/dy
2J mice (1.564.5;
1.464.7 respectively, P,0.01). Following treatment there was no
longer significant difference in MMP-2 and MMP-9 activity
between the treated dy
2J/dy
2J and WT groups.
Discussion
In muscular dystrophy following recurrent cycles of muscle
injury and repair regeneration fails and the contractile tissue is
replaced with fibrotic tissue and fat. In advanced stages of the
disease the abundant connective tissue (fibrosis) distorts normal
muscle architecture and is associated with severe muscle weakness
in both human muscular dystrophy patients and dy
2J/dy
2J mouse
model of congenital muscular dystrophy [8,28]. Fibrous tissue
Figure 3. The effect of FTS on muscle pathology. Digital images of hematoxylin and eosin stained muscle. (A) WT untreated mouse presenting
normal organization of muscle tissue with no abundant connective tissue. (B) Untreated dy
2J/dy
2J mouse showing severe dystrophic changes with
abnormal variation of fiber size, internal nuclei and severe fibrosis. (C) Treated dy
2J/dy
2J mouse, showing still variation in fiber size.
Magnification 6400.
doi:10.1371/journal.pone.0018049.g003
Figure 4. The effect of FTS on muscle histological fibrosis. (A) Digital images of sirius red stained muscle and (B) quantified collagen content
graph. A significant decrease in collagen content was observed in the FTS treated dy
2J/dy
2J compared to the untreated dy
2J/dy
2J mice (* P,0.02;
Student’s t-test). There was a significant difference between the WT and dy
2J/dy
2J groups (** P,0.05; Student’s t-test). Each bar represents the mean
6 SEM of five regions in each biopsy of five mice. Magnification 6400.
doi:10.1371/journal.pone.0018049.g004
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secretion of cytokines and growth factors, increased collagen and
other extra cellular matrix proteins. Protooncogens, in particular
Ras, play an important role in fibroblast proliferation. It has been
proposed that Ras proteins function as intermediates in signal
transduction initiated by a large variety of growth factors such as
epidermal growth factor (EGF) and platelet – derived growth
factor (PDGF) [29,30]. Ras proteins are attached to the inner side
of the plasma membrane where they are activated by cell surface
receptors to induce the conversion of the inactive Ras, guanosine-
diphosphate (GDP), to active Ras-GTP [12,31]. S- trans, trans
farnesythiosalicylic acid (FTS) is a unique and potent competitive
Ras inhibitor. FTS’s action is based on its ability to interact with
Ras anchorage domains, dislodging the protein from the
membrane attachment, and markedly accelerating Ras degrada-
tion [32,33].
The dy
2J/dy
2J mouse model of merosin deficient congenital
muscular dystrophy (MDC1A) is a useful model to study
pharmacological intervention on mouse strength and mobility
and muscle fibrosis. At the age of 6 weeks dy
2J/dy
2J mice are
significantly weaker than the C57BL/6J WT mice. In the ensuing
12 weeks muscle strength further decreases in the dy
2J/dy
2J while
increasing in the WT [3,34]. At that age muscle fibrosis
significantly increases in the dy
2J/dy
2J compared to the WT [25].
In this study we showed that FTS treatment significantly
decreased both Ras expression and activity in the dy
2J/dy
2J mouse
model of merosin deficient congenital muscular dystrophy. We
further showed that phosphorylation of ERK, a Ras downstream
protein, was high in dy
2J/dy
2J mice and was significantly decreased
following FTS treatment. Decreased Ras activity and expression
was associated with significantly reduced muscle fibrosis studied by
quantitative automated image analysis of the biopsies as well as
reduced quantitative muscle collagen content. We know from
earlier studies that Ras proteins are present in fibroblasts,
inflammatory and muscle cells [15,17–19]. Therefore each of
these cell populations can potentially be involved in the effects of
FTS. Our results are consistent with previous studies which
demonstrated effective anti-fibrotic effect of FTS in thioacetamide
(TAA) experimentally induced liver cirrhosis in rats [22]. FTS had
both preventive qualities by inhibiting hepatic stellate cell (HSC)
activation and proliferation, as well as partial reversal effect on
liver cirrhosis.
In addition, FTS treated dy
2J/dy
2J mice had significant
improvement in hind limb muscle strength which normalized
and was comparable to the WT strength at the end of the study.
However, the treated mice had no significant improvement in
mouse mobility on motion detection software (Figure S2). The
failure of improvement in mobility may be due to lack of effect in
the mouse forelimb strength. An alternative hypothesis is that
even though muscle strength is increased in the weak (hind) limbs,
the animal endurance for sustained effort was not improved. In
human studies muscle strength measurements (manual and
quantitative) and mobility parameters (6 minute walk test) are
separate outcome measures. In any case the lack of improvement
in mobility even though muscle strength was improved and
fibrosis was ameliorated may suggest that studying FTS as a
component of a combination therapy is worthwhile. Future
research direction may include studying the effect of FTS with
corticosteroids, or alternatively with Glatiramer acetate which
demonstrated improvement of strength and mobility in the same
mouse model [24].
The mechanism of the beneficial effect of FTS in this model of
muscular dystrophy is probably by decreasing inflammation and
fibrosis as has been shown in experimentally induced liver
cirrhosis, SLE, neuritis or nephritis animal models [13,14,-
15,22,23]. FTS has specificity towards Ras and Ras driven
inflammatory and fibroblasts cell growth, with the advantage that
it does not confer a global growth inhibitory effect on every type of
cell [35]. Our results indicate that MMP-2 and MMP-9
collagenolytic activities are significantly increased in the untreated
dy
2J/dy
2J compared to the WT groups and that FTS treatment
resulted in significant inhibition of both MMP-2 and MMP-9
activities. These findings support previous data implying metallo-
proteinase activity is regulated by Ras activity and suggest that
MMP- 2 & 9 inhibition is an important mechanism of fibrosis
inhibition by FTS in the dy
2J/dy
2J mouse. Matrix metalloproteases
(MMPs) play an important role during skeletal muscle degener-
ation, regeneration and in homeostasis and maintenance of
myofiber functional integrity [36]. MMPs influence cell motility,
interactions between cells, matrix degradation, tissue remodeling
Figure 5. The effect of FTS on muscle collagen content. Sircol collagen assay of muscle biopsies. Student’s t-test and non parametric Mann-
Whitney test showed a significant decreased in collagen level in the FTS treated dy
2J/dy
2J compared to the untreated group (*P,0.02; Student’s t-
test). There was a significant difference between the WT and dy
2J/dy
2J groups (** P,0.01; Student’s t-test). Each bar represents the mean 6 SEM of
seven mice.
doi:10.1371/journal.pone.0018049.g005
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commonly induced by cytokines and secreted by inflammatory
cells [38]. Over-expression of MMP-2 and MMP-9 on non-
necrotic fibers may facilitate lymphocyte adhesion and enhance T-
cell–mediated cytotoxicity by degrading ECM proteins [36].
MMP-2 plays essential roles in myofiber proliferation, differenti-
ation, fiber healing after injury, and maintenance of the
surrounding connective tissue [36,39]. It is expressed in myoblasts
and fibroblasts, within normal muscle tissue, and is over-expressed
in the ECM in many pathological conditions in response to various
initiating factors such as those occurring during inflammation,
myopathies, muscle atrophy, and excessive exercise [36]. MMP-2
activity was found to be associated with the extent of pathological
injury in mdx muscles, especially in the diaphragm [40] and
increased MMP-2 activity was demonstrated in a patient with
congenital muscular dystrophy [41]. MMP-9 up-regulation
appears to be an important molecular event in the multi-step
processes of muscle inflammation. It is strongly expressed in
atrophic myofibers, activated satellite cells and in invading T
lymphocytes [36,38,42,43].
Li H. et al recently reported that the expression of MMP-9 is
increased in dystrophic muscle and that its inhibition considerably
reduced inflammatory response, fibrosis, and enhanced muscle
regeneration in mdx mice [44]. Interestingly, our results differ from
previous data of the liver cirrhosis rat model which showed
increased MMP-2 and MMP-9 activities following FTS treatment.
The discrepancy between the findings in different animals and
diseases may also represent the fact that the role of each of these
MMPs has been found to be divergent in different stages of disease
progression [45].
Congenital muscular dystrophy with merosin deficiency is
associated with central and peripheral nervous system dysmyelina-
tion. Both children and dy
2J/dy
2J mice have peripheral neuropathy
in addition to progressive muscular dystrophy [7,8]. Increased Ras
activation was detected during Theiler’s murine encephalomyelitis
virus infection, a demyelinating disease that resembles human
multiple sclerosis [46] and inhibition of Ras activation was
suggested as a possible therapeutic directed against cytokine and
NO mediated neuroinflammatory and neurodegenerative disor-
ders [47]. An additional effect of Ras inhibition on the dy
2J/dy
2J
peripheral neuropathy can therefore be postulated. This hypoth-
esis was not evaluated in the current study.
The results of this study support previous findings that anti-
inflammatory and anti-fibrotic agents have significant beneficial
effect in the dy
2J/dy
2J and the mdx mouse models of muscular
dystrophy. Treatment with Glatiramer Acetate, an immune
modulating agent, resulted in significant improvement in hind
limb muscle strength, improvement of mouse mobility as well as
attenuation of the fibrosis markers vimentin and fibronectinin in
dy
2J/dy
2J mice [25]. Halofuginone an anti-fibrotic agent (pro-
collagen 1 inhibitor) treatment was associated with fibrosis
inhibition in both mdx and dy
2J/dy
2J mice [48]. Losartan treatment
resulted in improved muscle regeneration and diminished fibrosis
in the mdx mouse by TGF-b antagonism. After six months
treatment these mice showed increased strength and less muscle
fatigue compared to sham treated mice [49].
The positive results of the current trial support further studying
of FTS, an anti-fibrotic agent and a potent Ras inhibitor, as a
potential new treatment in congenital and possibly additional
forms of muscular dystrophy. Clinical studies using FTS for cancer
are currently performed. Phase I/II study dosing FTS (salira-
sib)+gemcitabine in pancreatic cancer patients and a phase II trial
of FTS treatment in lung cancer are underway (http://www.
concordiapharma.com). Future studies in other animal models of
muscular dystrophy such as the mdx mouse, FTS effect in
combination with other medications and safety data in children
are required towards consideration of studying FTS in human
clinical trials.
Figure 6. The effect of FTS on MMP-2 and MMP-9 activity. Densitometry graphs of Gelatin Zymography for MMP-2 and MMP-9. The
collagenolytic activities of MMP-2 and MMP-9 were significantly lower in the FTS treated dy
2J/dy
2Jcompared to the untreated group (*P,0.01;
Student’s t-test). There was a significant difference between the WT and dy
2J/dy
2J groups (** P,0.05; Student’s t-test). Each bar represents the mean
6 SEM of six mice.
doi:10.1371/journal.pone.0018049.g006
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Figure S1 Fore limb muscle strength in FTS treated and
untreated WT and dy
2J/dy
2J mice. The data of seven mice in
each group is expressed as mean 6 SEM. Repeated measures
ANOVA test showed no significant difference in the fore limb
strengths between the treated and untreated dy
2J/dy
2J and WT
groups. There was a significant difference between the WT and
dy
2J/dy
2J fore limb muscle strength (P,0.01).
(TIF)
Figure S2 The effect of FTS on mouse mobility. The data
of seven mice in each group is expressed as mean 6 SEM. No
significant difference was found between the treated and untreated
dy
2J/dy
2J mice in maximal distance (A), maximal velocity (B) total
distance (C) and mean velocity (D). Student’s t-test and non
parametric Mann-Whitney test showed significant difference in all
4 parameters between the WT and dy
2J/dy
2J untreated groups
(P,0.001).
(TIF)
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